Gene

FLT3

fms related receptor tyrosine kinase 3

Explore in graph →CI-GENE-00002044HGNC:3765 ENSG00000122025 NCBI 2322 CIViC Cancer geneApproved

Curated evidence

Clinical evidence (266)

CIViC items involving this gene, grouped by molecular profile and therapy, with native levels and directions. 50 items per page.

civicCuratedShowing 201–250 of 266 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
FLT3 S574del2
(functional)	—UNRESOLVED	Functional	D	Supports Gain Of Function	4	submitted

Cohorts

Alteration frequency by cohort (125)

Frequency = cases affected / cases profiled within one cohort. Cohorts are never pooled.

cbioportalObserved125 cohort rows (showing 50, sorted by frequency) · frequency = affected / profiled, as published by each cohort; cohorts are not pooled. Hover a row badge for its release.

Cohort	Mapped cancer	Alteration	Affected (n)	Profiled (n)	Frequency (%)	Rank in cohort	Source
Mixed Tumors - MiMSI Cohort (MSK, Nat Commun 2024) pancan_mimsi_msk_2024	unmapped	Ssm	142	5,033

Literature

Linked publications (46)

25 per page, newest first.

pubmedPublishedShowing 26–46 of 46 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Sunitinib in Patients with Metastatic Colorectal Cancer (mCRC) with FLT-3 Amplification: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.
· Target Oncol · 2020 · PMID 33068284 · validated civic_curation pubmed
Phase II study of the oral MEK inhibitor selumetinib in advanced acute myelogenous leukemia: a University of Chicago phase II consortium trial.
· Clin Cancer Res · 2014 · PMID 24178622 · validated civic_curation pubmed
A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease.
· Blood · 2005 · PMID 15459012 · validated civic_curation pubmed
Comprehensive genomic analysis reveals FLT3 activation and a therapeutic strategy for a patient with relapsed adult B-lymphoblastic leukemia.

FLT3 S963L1
(oncogenic)	Malignant Mesothelioma	Oncogenic	C	Does Not Support Oncogenicity	1	submitted	EID13209 FFPE samples from 11 malignant mesothelioma patients were sequenced. In one patient, who was 63 and F, with Epithelioid subtype and Pleural origin, FLT3 S963L was found, together with BCL6 R459C, EP30… (full text at CIViC) PMID 27127140 · Ugurluer et al., 2016 · Open in CIViC	civic

FLT3 S963L1

(oncogenic)

Malignant Mesothelioma

Oncogenic

Does Not Support Oncogenicity

submitted

EID13209

FFPE samples from 11 malignant mesothelioma patients were sequenced. In one patient, who was 63 and F, with Epithelioid subtype and Pleural origin, FLT3 S963L was found, together with BCL6 R459C, EP30… (full text at CIViC)

PMID 27127140 · Ugurluer et al., 2016 · Open in CIViC

FLT3 TKD MUTATION7
(prognostic)	Acute Myeloid LeukemiaCURATED_BROADER	Prognostic	B	Supports Poor Outcome	4	accepted	EID373 In AML patients, FLT3-TKD mutation was associated with poorer disease free survival compared to patients with wild type FLT3. PMID 17940205 · Whitman et al., 2008 · Open in CIViC	civic
〃	Acute Myeloid LeukemiaCURATED_BROADER	Prognostic	B	Supports Better Outcome	3	accepted	EID171 Event-free survival was significantly improved in patients with both NPM1 and FLT3-TKD mutations compared to patients with 1) FLT3-TKD mutations alone 2) either NPM1 or FLT3-TKD when FLT3-ITD patients… (full text at CIViC) PMID 17965322 · Bacher et al., 2008 · Open in CIViC	civic
(diagnostic)	Acute Myeloid LeukemiaCURATED_BROADER	Diagnostic	B	Does Not Support Positive	3	accepted	EID214 WBC counts were not significantly different in AML patients with FLT3 D835 mutations compared to wild type. PMID 11290608 · Yamamoto et al., 2001 · Open in CIViC	civic
(prognostic)	Acute Myeloid LeukemiaCURATED_BROADER	Prognostic	B	Does Not Support N/A	3	accepted	EID322 AML patients with D835 mutation of FLT3 did not have worse overall survival than patients with wild type FLT3. PMID 11290608 · Yamamoto et al., 2001 · Open in CIViC	civic
〃	Acute Myeloid LeukemiaCURATED_BROADER	Prognostic	B	Supports Poor Outcome	3	submitted	EID9246 This study compares the genetic drivers identified in a relatively young population of patients with AML across three multicenter clinical trials (AML-HD98A, AML-HD98B, and AMLSG-07-04). FLT3 (both IT… (full text at CIViC) PMID 27276561 · Papaemmanuil et al., 2016 · Open in CIViC	civic
Midostaurin	Acute Myeloid LeukemiaCURATED_BROADER	Predictive	B	Supports Sensitivity Response	3	accepted	EID1295 In a phase 2 clinical study of 95 AML/high-risk MDS patients treated with either 50 or 100 mg midostaurin, 35 harbored FLT3 mutations (26 had FLT3 ITD, 9 had FLT3 D835Y mutations). A higher percentage… (full text at CIViC) PMID 20733134 · Fischer et al., 2010 · Open in CIViC	civic
Sorafenib	Acute Myeloid LeukemiaCURATED_BROADER	Predictive	B	Supports Resistance	4	accepted	EID248 Sorafenib is effective in patients with FLT3 internal tandem repeat mutations, but not in patients with wild type or D835 mutation. PMID 18230792 · Zhang et al., 2008 · Open in CIViC	civic

FLT3 V592_D593INSDFREY4
Palbociclib	Acute Myeloid LeukemiaCURATED_BROADER	Predictive	D	Supports Sensitivity Response	—	submitted	EID4742 In an in vitro study, MOLM-14, PL21 and MV4-11 cell lines expressing FLT3 internal tandem duplication mutation (FLT3-ITD) demonstrated increased sensitivity to palbociclib treatment, compared to THP-1… (full text at CIViC) PMID 27099147 · Uras et al., 2016 · Open in CIViC	civic
Sunitinib	Acute Myeloid LeukemiaCURATED_BROADER	Predictive	C	Supports Sensitivity Response	—	submitted	EID4739 In a retrospective study of 15 acute myeloid leukemia patients, the patients with FLT3 internal tandem duplication mutation (n=2) were associated with improved response to sunitinib treatment. The pat… (full text at CIViC) PMID 15459012 · Fiedler et al., 2005 · Open in CIViC	civic
〃	Acute Myeloid LeukemiaCURATED_BROADER	Predictive	C	Supports Sensitivity Response	—	submitted	EID4740 In a phase I study of 29 acute myeloid leukemia patients, patients with FLT3 internal tandem duplication (ITD) mutation (n=3) were associated with improved response to sunitinib monotherapy compared … (full text at CIViC) PMID 14654525 · O'Farrell et al., 2003 · Open in CIViC	civic
〃	Acute Myeloid LeukemiaCURATED_BROADER	Predictive	D	Supports Sensitivity Response	—	submitted	EID4741 In an in vitro study, leukemia M4;11 (endogenous), myeloid 32D (overexpression) and Chinese hamster ovary (transient expression) cell lines expressing FLT3 internal tandem duplication mutation demonst… (full text at CIViC) PMID 12531805 · O'Farrell et al., 2003 · Open in CIViC	civic

FLT3 V592I3
(oncogenic)	Acute Myeloid LeukemiaCURATED_BROADER	Oncogenic	C	Supports Oncogenicity	2	rejected	EID12964 Longitudinal study analyzing blood samples over time for CHIP. The V592I was found with a VAF 0.53% (below normal CHIP threshold) in a control individual who did not develop AML. PMID 31004019 · Young et al., 2019 · Open in CIViC	civic
〃	Acute Myeloid LeukemiaCURATED_BROADER	Oncogenic	C	Supports Oncogenicity	2	submitted	EID12965 Found in whole blood of patient (ID# 4973, appendix 2) with AML, mutational profile included FLT3 V592I VAF 55%; FLT3-ITD VAF 25%, NPM1 c.863_864insCCTG VAF 25%, DNMT3A p.Arg882His VAF 43% PMID 37586297 · Hogg et al., 2023 · Open in CIViC	civic
〃	Myeloproliferative NeoplasmCURATED_BROADER	Oncogenic	C	Supports Oncogenicity	2	submitted	EID12966 Patient 8207 (Appendix 2) with MPN and mutational profile FLT3 V592I VAF 53%; ZRSR2 p.Cys172Tyr VAF 81% and CALR c.1154_1155insTTGTC VAF 80% PMID 37586297 · Hogg et al., 2023 · Open in CIViC	civic